Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy

References

• Huang, B. L., S. Chandra, and D. Q. Shih. 2012. Skin manifestations of inflammatory bowel disease. Front. Physiol. 3: 13
   PubMed Web of Science ®Google Scholar
• Vavricka, S. R., L. Brun, P. Ballabeni, et al. 2011. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am. J. Gastroenterol. 106: 110–119
   PubMed Web of Science ®Google Scholar
• Veloso, F. T., J. Carvalho, and F. Magro. 1996. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J. Clin. Gastroenterol. 23: 29–34
   PubMed Web of Science ®Google Scholar
• Rankin, G. B., H. D. Watts, C. S. Melnyk, and M. L. KelleyJr. 1979. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 77: 914–920
   PubMed Web of Science ®Google Scholar
• Williams, H., D. Walker, and T. R. Orchard. 2008. Extraintestinal manifestations of inflammatory bowel disease. Curr. Gastroenterol. Rep. 10: 597–605
   PubMedGoogle Scholar
• Ardizzone, S., P. S. Puttini, A. Cassinotti, and G. B. Porro. 2008. Extraintestinal manifestations of inflammatory bowel disease. Dig. Liver Dis. 40: S253–259
   Google Scholar
• Danese, S., S. Semeraro, A. Papa, et al. 2005. Extraintestinal manifestations in inflammatory bowel disease. World J. Gastroenterol. 11: 7227–7236
   PubMed Web of Science ®Google Scholar
• Burgdorf, W. 1981. Cutaneous manifestations of Crohn’s disease. J. Am. Acad. Dermatol. 5: 689–695
   PubMed Web of Science ®Google Scholar
• Palamaras, I., J. El-Jabbour, N. Pietropaolo, et al. 2008. Metastatic Crohn's disease: a review. J. Eur. Acad. Dermatol. Venereol. 22: 1033–1043
   PubMed Web of Science ®Google Scholar
• Timani, S., and D. F. Mutasim. 2008. Skin manifestations of inflammatory bowel disease. Clin. Dermatol. 26: 265–273
   PubMed Web of Science ®Google Scholar
• Trost, L. B., and J. K. McDonnell. 2005. Important cutaneous manifestations of inflammatory bowel disease. Postgrad. Med. J. 81: 580–585
   PubMed Web of Science ®Google Scholar
• Passarini, B., S. D. Infusino, E. Barbieri, et al. 2007. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy. Dermatology 215: 295–300
   PubMed Web of Science ®Google Scholar
• Mnif, L., A. Amouri, and N. Tahri. 2010. Cutaneous manifestations of inflammatory bowel disease. Tunis. Med. 88: 420–423
   PubMedGoogle Scholar
• Levine, J. S., and R. Burakoff. 2011. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol. Hepatol. (N Y) 7: 235–241
   PubMedGoogle Scholar
• Prefontaine, E., L. R. Sutherland, J. K. Macdonald, and M. Cepoiu. 2009. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev. 1: CD000067
   PubMed Web of Science ®Google Scholar
• Leung, Y., R. Panaccione, B. Hemmelgarn, and J. Jones. 2008. Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis. Dig. Dis. Sci. 53: 1455–1461
   PubMed Web of Science ®Google Scholar
• Fraser, A. G., T. R. Orchard, and D. P. Jewell. 2002. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 50: 485–489
   PubMed Web of Science ®Google Scholar
• Chebli, L. A., L. D. Chaves, F. F. Pimentel, et al. 2010. Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis. Inflamm. Bowel Dis. 16: 613–619
   PubMed Web of Science ®Google Scholar
• Bradford, K., and D. Q. Shih. 2011. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J. Gastroenterol. 17: 4166–4173
   PubMed Web of Science ®Google Scholar
• Moloney, F. J., H. Comber, P. O’Lorcain, et al. 2006. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br. J. Dermatol. 154: 498–504
   PubMed Web of Science ®Google Scholar
• Patel, A. A., R. A. Swerlick, and C. O. McCall. 2006. Azathioprine in dermatology: the past, the present, and the future. J. Am. Acad. Dermatol. 55: 369–389
   PubMed Web of Science ®Google Scholar
• Jensen, P., S. Hansen, B. Møller, et al. 1999. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J. Am. Acad. Dermatol. 40: 177--186
   PubMed Web of Science ®Google Scholar
• van den Reek, J. M., P. P. van Lümig, M. Janssen, et al. 2012. Increased incidence of squamous cell carcinoma of the skin after long-term treatment with azathioprine in patients with auto-immune inflammatory rheumatic diseases. J. Eur. Acad. Dermatol. Venereol. [Epub ahead of print]. doi: 10.1111/jdv.12041
   Google Scholar
• Perrett, C. M., S. L. Walker, P. O'Donovan, et al. 2008. Azathioprine treatment photosensitizes human skin to ultraviolet A radiation. Br. J. Dermatol. 159: 198–204
   PubMed Web of Science ®Google Scholar
• O’Donovan, P., C. M. Perrett, X. Zhang, et al. 2005. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 309: 1871–1874
   PubMed Web of Science ®Google Scholar
• Mellemkjaer, L., J. H. Olsen, M. Frisch, et al. 1995. Cancer in patients with ulcerative colitis. Int. J. Cancer. 60: 330–333
   PubMed Web of Science ®Google Scholar
• Greenstein, A. J., R. Gennuso, D. B. Sachar, et al. 1985. Extraintestinal cancers in inflammatory bowel disease. Cancer 56: 2914–2921
   PubMed Web of Science ®Google Scholar
• Fraser, A. G., T. R. Orchard, E. M. Robinson, and D.P. Jewell. 2002. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment. Pharmacol. Ther. 16: 1225–1232
   PubMed Web of Science ®Google Scholar
• Long, M. D., H. H. Herfarth, C. A. Pipkin, et al. 2010. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 8: 268–274
   PubMed Web of Science ®Google Scholar
• van Schaik, F. D., M. G. van Oijen, H. M. Smeets, et al. 2011. Risk of nonmelanoma skin cancer in patients with inflammatory bowel disease who use thiopurines is not increased. Clin. Gastroenterol. Hepatol. 9: 449–450
   PubMedGoogle Scholar
• Setshedi, M., D. Epstein, T. A. Winter, et al. 2012. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J. Gastroenterol. Hepatol. 27: 385–389
   PubMed Web of Science ®Google Scholar
• Singh, H., Z. Nugent, A. A. Demers, and C. N. Bernstein. 2011. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 141: 1612–1620
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet, L., K. Khosrotehrani, F. Carrat, et al. 2011. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 141: 1621–1628
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet, L., J. B. Chevaux, A. M. Bouvier, et al. 2012. Risk of melanoma in patients who receive thiopurines for inflammatory bowel disease is not increased. Am. J. Gastroenterol. 107: 1443–1444
   PubMed Web of Science ®Google Scholar
• Govani, S. M., and P. D. Higgins. 2010. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. J. Crohns Colitis 4: 444–449
   PubMed Web of Science ®Google Scholar
• Gupta, G., E. Lautenbach, and J. D. Lewis. 2006. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 4: 1483–1490
   PubMed Web of Science ®Google Scholar
• Millar, J. W., and N. W. Horne. 1979. Tuberculosis in immunosuppressed patients. Lancet 1: 1176–1178
   PubMed Web of Science ®Google Scholar
• Mayo, J. M., M. B. Colmenarejo, P. J. Vaquerizo, and M. V. Gutierrez. 2004. Hypersensitivity reaction to azathioprine in a patient with ulcerative colitis. Infrequent manifestations. Inflamm. Bowel Dis. 10: 700
   PubMed Web of Science ®Google Scholar
• Bidinger, J. J., K. Sky, D. F. Battafarano, and J. S. Henning. 2011. The cutaneous and systemic manifestations of azathioprine hypersensitivity syndrome. J. Am. Acad. Dermatol. 65: 184–191
   PubMed Web of Science ®Google Scholar
• Yiasemides, E., and G. Thom. 2009. Azathioprine hypersensitivity presenting as a neutrophilic dermatosis in a man with ulcerative colitis. Australas. J. Dermatol. 50: 48–51
   PubMed Web of Science ®Google Scholar
• de Fonclare, A. L., K. Khosrotehrani, S. Aractingi, et al. 2007. Erythema nodosum-like eruption as a manifestation of azathioprine hypersensitivity in patients with inflammatory bowel disease. Arch. Dermatol. 143: 744–748
   PubMedGoogle Scholar
• Thomson, A. B., M. Gupta, and H. J. Freeman. 2012. Use of the tumor necrosis factor-blockers for Crohn's disease. World J. Gastroenterol. 18: 4823–4854
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet, L., P. Deltenre, N. de Suray, et al. 2008. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebocontrolled trials. Clin. Gastroenterol. Hepatol. 6: 644–653
   PubMed Web of Science ®Google Scholar
• Hommes, D. W., B. Oldenburg, A. A. van Bodegraven, et al. 2006. Guidelines for treatment with infliximab for Crohn's disease. Neth. J. Med. 64: 219–229
   PubMed Web of Science ®Google Scholar
• Etchevers, M. J., I. Ordás, and E. Ricart. 2010. Optimizing the use of tumour necrosis factor inhibitors in Crohn's disease: a practical approach. Drugs 70: 109–120
   PubMed Web of Science ®Google Scholar
• Hoentjen, F., and A. A. van Bodegraven. 2009. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J. Gastroenterol. 15: 2067–2073
   PubMed Web of Science ®Google Scholar
• Colombel, J. F., W. J. Sandborn, and P. Rutgeerts. 2007. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132: 52–65
   PubMed Web of Science ®Google Scholar
• Sandborn, W. J., B. G. Feagan, S. Stoinov, et al. 2007. Certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357: 228–238
   PubMed Web of Science ®Google Scholar
• Cheifetz, A., M. Smedley, S. Martin, et al. 2003. The incidence and management of infusion reactions to infliximab: a large center experience. Am. J. Gastroenterol. 98: 1315–1324
   PubMed Web of Science ®Google Scholar
• Vermeire, S., G. Van Assche, and P. Rutgeerts. 2009. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Best Pract. Res. Clin. Gastroenterol. 23: 101–112
   PubMed Web of Science ®Google Scholar
• Toruner, M., E. V. Loftus Jr, W. S. Harmsen, et al. 2008. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134: 929–936
   PubMed Web of Science ®Google Scholar
• Stallmach, A., S. Hagel, and T. Bruns. 2010. Adverse effects of biologics used for treating IBD. Best Pract. Res. Clin. Gastroenterol. 24: 167–182
   PubMed Web of Science ®Google Scholar
• Cullen, G., R. P. Baden, and A. S. Cheifetz. 2012. Varicella zoster virus infection in inflammatory bowel disease. Inflamm. Bowel Dis. 18: 2392–2403
   PubMed Web of Science ®Google Scholar
• Long M. D., C. Martin, R. S. Sandler, and M. D. Kappelman. 2013. Increased risk of herpes zoster among 108,604 patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 37: 420–429
   PubMed Web of Science ®Google Scholar
• Shale, M. J., C. H. Seow, C. S. Coffin, et al. 2010. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment. Pharmacol. Ther. 31: 20–34
   PubMed Web of Science ®Google Scholar
• Nancey, S., G. Boschetti, E. Cotte, et al. 2011. Multiple and fulminant cutaneous squamous cell carcinomas in a Crohn's disease patient treated with immunosuppressants and adalimumab. Inflamm. Bowel Dis. 17: 1060–1061
   PubMed Web of Science ®Google Scholar
• Fidder, H., F. Schnitzler, M. Ferrante, et al. 2009. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single center cohort study. Gut 58: 501–508
   PubMed Web of Science ®Google Scholar
• Katoulis, A. C., A. Kanelleas, G. Zambacos, et al. 2010. Development of two primary malignant melanomas after treatment with adalimumab: a case report and review of the possible link between biological therapy with TNF-alpha antagonists and melanocytic proliferation. Dermatology 221: 9–12
   PubMed Web of Science ®Google Scholar
• Long, M. D., C. F. Martin, C. A. Pipkin, et al. 2012. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 143: 390–399
   PubMed Web of Science ®Google Scholar
• Rojas-Feria, M., M. Eslam, M. Castro-Fernandez, et al. 2011. Cutaneous lymphoma in a patient with ulcerative colitis after immunosuppressive therapy. J Crohns Colitis 5: 608–611
   PubMed Web of Science ®Google Scholar
• Herrinton, L. J., L. Liu, X. Weng, et al. 2011. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am. J. Gastroenterol. 106: 2146–2153
   PubMed Web of Science ®Google Scholar
• Wang, L. C., M. M. Medenica, C. R. Shea, and S. Busbey. 2003. Infliximab induced eczema like purpura of Doucas and Kapfenakis. J. Am. Acad. Dermatol. 49: 157–158
   PubMed Web of Science ®Google Scholar
• Flendrie, M., W. H. Vissers, M. C. Creemers, et al. 2005. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res. Ther. 7: R666–R676
   PubMed Web of Science ®Google Scholar
• Esmailzadeh, A., P. Yousefi, D. Farhi, et al. 2009. Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients. Dermatology 219: 263–267
   PubMed Web of Science ®Google Scholar
• Pathirana, D., A. D. Ormerod, P. Saiag, et al. 2009. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J. Eur. Acad. Dermatol. Venereol. 23: 1–70
   PubMed Web of Science ®Google Scholar
• Fiorino, G., M. Allez, A. Malesci, and S. Danese. 2009. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 29: 921–927
   PubMed Web of Science ®Google Scholar
• Nestle, F. O., C. Conrad, A. Tun-Kyi, et al. 2005. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J. Exp. Med. 202: 135–143
   PubMed Web of Science ®Google Scholar
• Gilliet, M., C. Conrad, M. Geiges, et al. 2004. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch. Dermatol. 140: 1490–1495
   PubMed Web of Science ®Google Scholar
• Guerra, I., A. Algaba, J. L. Pérez-Calle, et al. 2012. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J. Crohns Colitis 6: 518–523
   PubMed Web of Science ®Google Scholar
• Denadai, R., F. V. Teixeira, and R. Saad-Hossne. 2012. Letter: pathogenesis of tumour necrosis factor-alpha antagonists-induced psoriasiform lesions. Aliment. Pharmacol. Ther. 36: 77–78
   PubMed Web of Science ®Google Scholar
• Iborra, M., B. Beltrán, G. Bastida, et al. 2011. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect. J. Crohns Colitis 5: 157–161
   PubMed Web of Science ®Google Scholar
• Rahier, J. F., S. Buche, and L. Peyrin-Biroulet. 2010. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin. Gastroenterol. Hepatol. 8: 1048–1055
   PubMed Web of Science ®Google Scholar
• Wollina, U., G. Hansel, A. Koch, et al. 2008. Tumor necrosis factor-a inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am. J. Clin. Dermatol. 9: 1–14
   PubMed Web of Science ®Google Scholar
• Shmidt, E., D. A. Wetter, S. B. Ferguson, and M. R. Pittelkow. 2012. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010. J. Am. Acad. Dermatol. 67: e179–185
   Google Scholar
• Cullen, G., D. Kroshinsky, A. S. Cheifetz, and J. R. Korzenik. 2011. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment. Pharmacol. Ther. 34: 1318–1327
   PubMed Web of Science ®Google Scholar
• Asarch, A., A. B. Gottlieb, J. Lee, et al. 2009. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J. Am. Acad. Dermatol. 61: 104–111
   PubMed Web of Science ®Google Scholar
• Vergara, G., J. F. Silvestre, I. Betlloch, et al. 2002. Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch. Dermatol. 138: 1258–1259
   PubMed Web of Science ®Google Scholar
• De Simone, C., G. Caldarola, M. D’Agostino, et al. 2008. Lichenoid reaction induced by adalimumab. J. Eur. Acad. Dermatol. Venereol. 22: 626–627
   PubMed Web of Science ®Google Scholar
• Flendrie, M., W. H. Vissers, M. C. Creemers, et al. 2005. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res. Ther. 7: R666–676
   PubMed Web of Science ®Google Scholar
• Seneschal, J., S. Lepreux, M. L. Bouyssou-Gauthier, et al. 2007. Psoriasiform drug eruptions under anti-TNF treatment of arthritis are not true psoriasis. Acta Derm. Venereol. 87: 77–80
   PubMed Web of Science ®Google Scholar
• Devos, S. A., N. Van Den Bossche, M. De Vos, and J. M. Naeyaert. 2003. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 206: 388–390
   PubMed Web of Science ®Google Scholar
• Costa, M. F., N. R. Said, and B. Zimmermann. 2008. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin. Arthritis Rheum. 37: 381–387
   PubMed Web of Science ®Google Scholar
• De Bandt, M. 2006. Lessons for lupus from tumor necrosis factor blockade. Lupus 15: 762–767
   PubMed Web of Science ®Google Scholar
• Marzano, A. V., P. Vezzoli, and C. Crosti. 2009. Drug induced lupus: an update on its dermatological aspects. Lupus 18: 935–940
   PubMed Web of Science ®Google Scholar
• Williams, V. L., and P. R. Cohen. 2011. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int. J. Dermatol. 50: 619–625
   PubMed Web of Science ®Google Scholar
• Wetter, D. A., and M. D. P. Davis. 2009. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clinic Proc. 84: 979–984
   PubMed Web of Science ®Google Scholar
• Costa, M. F., N. R. Said, and B. Zimmermann. 2008. Drug induced lupus due to anti-tumor necrosis factor alpha agents. Semin. Arthritis Rheum. 37: 381–387
   PubMed Web of Science ®Google Scholar
• Dalle Vedove, C., J. C. Simon, and G. Girolomoni. 2012. Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNFα agents. J. Dtsch. Dermatol. Ges. 10: 889–897
   PubMed Web of Science ®Google Scholar
• De Bant, M., J. Sibilia, X. Le Loet, et al. 2005. Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: a French national survey. Arthritis Res. Ther. 7: R545–R551
   Google Scholar
• Marzano, A. V., R. Lazzari, I. Polloni, et al. 2011. Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart. Br. J. Dermatol. 165: 335–341
   PubMed Web of Science ®Google Scholar
• Bout-Tabaku, S., R. Rivas-Chacon, and R. Restrepo. 2007. Systemic lupus erythematosus in a patient with etanercept for polyarticular juvenile rheumatoid arthritis. J. Rheumatol. 34: 2503–2504
   PubMed Web of Science ®Google Scholar
• Via, C. S., A. Shustov, V. Rus, et al. 2001. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J. Immunol. 167: 6821–6826
   PubMed Web of Science ®Google Scholar
• Chang, C., and M. E. Gershwin. 2011. Drug-induced lupus erythematosus. Incidence, management and prevention. Drug Saf. 34: 357–374
   PubMed Web of Science ®Google Scholar
• Marzano, A. V., A. Frezzolini, M. Caproni, et al. 2007. Immunohistochemical expression of apoptotic markers in drug-induced erythema multiforme, Stevens Johnson syndrome and toxic epidermal necrolysis. Int. J. Immunopathol. Pharmacol. 20: 557–566
   PubMed Web of Science ®Google Scholar
• Erikkson, C., S. Engstrand, K. G. Sundqvist, and S. Rantapää-Dahlqvist. 2005. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann. Rheum. Dis. 64: 403–407
   PubMed Web of Science ®Google Scholar
• Saint Marcoux, B., and M. De Bandt. 2006. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 73: 710–713
   PubMed Web of Science ®Google Scholar
• Deng, A., V. Harvey, B. Sina, et al. 2006. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch. Dermatol. 142: 198–202
   PubMed Web of Science ®Google Scholar
• Voulgari, P. V., T. E. Markatseli, S. A. Exarchou, et al. 2008. Granuloma annulare induced by anti-tumor necrosis factor therapy. Ann. Rheum. Dis. 67: 567–570
   PubMed Web of Science ®Google Scholar
• Sun, G., C. A. Wasko, and S. Hsu. 2008. Acneiform eruption following anti-TNF-alpha treatment: a report of 3 cases. J. Drugs Dermatol. 7: 69–71
   PubMed Web of Science ®Google Scholar
• Takahashi, H., K. Kaneta, M. Honma, et al. 2010. Sarcoidosis during infliximab therapy for Crohn's disease. J. Dermatol. 37: 471–474
   PubMed Web of Science ®Google Scholar
• Doyle, L. A., L. C. Sperling, S. Baksh, et al. 2011. Psoriatic alopecia/alopecia areata-like reactions secondary to anti-tumor necrosis factor-α therapy: a novel cause of noncicatricial alopecia. Am. J. Dermatopathol. 33: 161–166
   PubMed Web of Science ®Google Scholar
• Lee, H. Y., N. Pelivani, H. Beltraminelli, et al. 2011. Amicrobial pustulosis-like rash in a patient with Crohn's disease under anti-TNF-alpha blocker. Dermatology 222: 304–310
   PubMed Web of Science ®Google Scholar
• Marzano, A. V., F. Capsoni, E. Berti, et al. 1996. Amicrobial pustular dermatosis of cutaneous folds associated with autoimmune disorders: a new entity? Dermatology 193: 88–93
   PubMed Web of Science ®Google Scholar